ArticleFrontiers in toxicology2026
Evaluation and investigation of the cardiotoxicity of the potential anti-cholangiocarcinoma drug lanatoside C.
Article in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Lanatoside C (Lan C), a cardiac glycoside, has demonstrated potent anti-cholangiocarcinoma activity. However, its potential cardiotoxicity at therapeutic doses remains poorly understood. This study aimed to systematically evaluate the cardiotoxicity of Lan C at cellular and organ levels and to elucidate its underlying molecular mechanisms. Methods: Human AC16 cardiomyocytes (ATCC® CRL-3568™) were employed for Results: Lan C showed a dose-dependent inhibitory effect Conclusion: Lan C exhibits measurable but relatively low cardiotoxicity at concentrations effective against cholangiocarcinoma, with cardiac effects may be manageable at therapeutic doses. These findings support Lan C as a promising anti-tumor candidate with controllable cardiotoxicity under optimized dosing and clinical monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.